文献速递骨软组织肉瘤与黑色素瘤

每周白蛋白结合型紫杉醇治疗儿童复发或难治性实体瘤的II期研究结果

Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network.
PubMed 文献 · Eur J Cancer · 2020-06-15

该研究为I/II期研究的II期部分,评估每周白蛋白结合型紫杉醇单药治疗儿童复发或难治性尤文肉瘤、神经母细胞瘤和横纹肌肉瘤的疗效与安全性。

要点

  • 每周白蛋白结合型紫杉醇240 mg/m2在儿童复发/难治性实体瘤中活性有限。
  • 尤文肉瘤和神经母细胞瘤未见客观缓解,横纹肌肉瘤ORR为7.1%。
  • 常见III/IV级不良事件为血液学毒性,周围神经病变见于横纹肌肉瘤组2例(14%)。

核心结论

  • 每周白蛋白结合型紫杉醇单药在儿童复发或难治性尤文肉瘤、神经母细胞瘤和横纹肌肉瘤中活性有限,但安全性得到确认。

研究设计与样本

  • 患者接受白蛋白结合型紫杉醇240 mg/m2,每28天周期第1、8、15天给药。
  • 主要终点为总缓解率(ORR;完全缓解+部分缓解),次要终点包括缓解持续时间、疾病控制率(DCR)、无进展生存期、1年总生存率、安全性和药代动力学。

主要发现

  • 尤文肉瘤、神经母细胞瘤和横纹肌肉瘤的ORR分别为0%、0%和7.1%(1例确认的部分缓解)。
  • DCR分别为30.8%(4例疾病稳定)、7.1%(1例疾病稳定)和7.1%(1例确认的部分缓解和0例疾病稳定)。
  • 中位无进展生存期分别为13.0周、7.4周和5.1周,1年总生存率分别为48%、25%和15%。
  • 最常见的III/IV级不良事件为血液学毒性:中性粒细胞减少(50%)和贫血(48%);横纹肌肉瘤组2例(14%)发生III/IV级周围神经病变。
  • 药代动力学分析显示紫杉醇组织分布迅速且广泛。

临床怎么用

  • 每周白蛋白结合型紫杉醇单药在儿童复发或难治性尤文肉瘤、神经母细胞瘤和横纹肌肉瘤中抗肿瘤活性有限,需谨慎评估其应用价值。
  • 治疗期间应密切监测血液学毒性和周围神经病变。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The phase I component of a phase I/II study defined the recommended phase II dose and established the tolerability of nab-paclitaxel monotherapy in paediatric patients with recurrent or refractory solid tumours. The activity and safety of nab-paclitaxel monotherapy was further investigated in this phase II study. PATIENTS AND METHODS: Paediatric patients with recurrent or refractory Ewing sarcoma, neuroblastoma or rhabdomyosarcoma received 240 mg/m2 of nab-paclitaxel on days 1, 8 and 15 of each 28-day cycle. The primary end-point was the overall response rate (ORR; complete response [CR] + partial response [PR]). Secondary end-points included duration of response, disease control rate (DCR; CR + PR + stable disease [SD]), progression-free survival, 1-year overall survival, safety and pharmacokinetics. RESULTS: Forty-two patients were enrolled, 14 each with Ewing sarcoma, neuroblastoma and rhabdomyosarcoma. The ORRs were 0%, 0% and 7.1% (1 confirmed PR), respectively. The DCRs were 30.8% (4 SD), 7.1% (1 SD) and 7.1% (1 confirmed PR and 0 SD) in the Ewing sarcoma, neuroblastoma and rhabdomyosarcoma groups, respectively. The median progression-free survival was 13.0, 7.4 and 5.1 weeks, respectively, and the 1-year overall survival rates were 48%, 25% and 15%, respectively. The most common grade III/4IVadverse events were haematologic (neutropenia [50%] and anaemia [48%]), and grade III/IV peripheral neuropathy occurred in 2 patients (14%) in the rhabdomyosarcoma group. Pharmacokinetics analyses revealed that paclitaxel tissue distribution was both rapid and extensive. CONCLUSIONS: In this phase II study, limited activity was observed; however, the safety of nab-paclitaxel in paediatric patients was confirmed. TRIAL REGISTRATION: NCT01962103 and EudraCT 2013-000144-26.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Amoroso L, Castel V, Bisogno G, et al. Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network. Eur J Cancer. 2020. PMID: 32554315. doi:10.1016/j.ejca.2020.04.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。